证券代码：000915 证券简称：华特达因 编号：2023-005 山东华特达因健康股份有限公司投资者关系活动记录表 ☑特定对象调研 □分析师会议 投资者关系活 □媒体采访 □业绩说明会 动类别 □新闻发布会 □路演活动 □现场参观 □其他 | --- | --- | --- | --- | --- | |--------------|---------------------|----------------|-------------------------|--------------| | | 公司 2023 | | | | | | | | | | | | 光大证券 | 黄素青、石崎良 | 兴业证券 | 董晓洁 | | | 浙商证券 | 毛雅婷 | 上海尚雅投资 | 张晔 | | | 光 大 机 构 业 务部 | 孙珣 | 中国人保资产 | 田垒 | | | 光 大 新 鸿 基 客户 | David Li | 建信养老 | 谭翔宇 | | | 深圳翼虎投资 | 黄琦 | 高毅资产 | 万明亮 | | | 创金合信基金 | 皮劲松 | 信达澳亚基金 | 李东升 | | | Dymon Asia | 陈继 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,153,217,104.50, a decrease of 5.88% compared to CNY 1,225,199,135.70 in the same period last year[20]. - Net profit attributable to shareholders of the listed company increased by 5.65% to CNY 321,841,708.90 from CNY 304,643,012.93 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was CNY 302,626,154.93, reflecting a 2.19% increase from CNY 296,135,957.10 in the previous year[20]. - The net cash flow from operating activities was CNY 592,107,241.53, down 2.09% from CNY 604,737,351.83 in the same period last year[20]. - Basic earnings per share rose by 5.38% to CNY 1.37, compared to CNY 1.30 in the previous year[20]. - Total assets at the end of the reporting period were CNY 4,623,381,525.86, a decrease of 1.43% from CNY 4,690,492,822.90 at the end of the previous year[20]. - Net assets attributable to shareholders of the listed company increased by 5.20% to CNY 2,718,464,789.51 from CNY 2,584,088,268.61 at the end of the previous year[20]. - The weighted average return on net assets decreased by 1.19 percentage points to 11.86% from 13.05% in the previous year[20]. Business Operations - The company's main business is in the pharmaceutical sector, with revenue from the pharmaceutical industry amounting to CNY 1.131 billion, accounting for 98.09% of total operating income[27]. - The company focuses on children's health products, with its flagship product "Yikexin" being a well-known brand in China, maintaining the highest market share in its category[28]. - The company has developed a range of children's health products, including probiotics, calcium supplements, and vitamin D drops, enhancing its product portfolio[28]. - The company has been committed to the mission of improving children's health since 2007, focusing on research and development in the children's health sector[28]. - The company has a diverse product line that includes various forms of children's medications and health products, catering to different health needs[28]. - The company continues to expand its market presence in the children's health sector, leveraging its established brand reputation[28]. Research and Development - The company is investing in research and development for innovative health solutions, with a budget allocation of 5 million yuan for the upcoming year[30]. - The company has established the first children's drug research center and children's drug research institute in China, enhancing its R&D capabilities and product line[34]. - The company has filed for 9 patents during the reporting period, including 7 invention patents, with 6 patents granted[41]. Market Strategy - The company projects a revenue growth forecast of 10% for the next fiscal year, supported by new product launches and market expansion strategies[30]. - New product developments include the introduction of a zinc supplement specifically targeting children's health issues, which is expected to capture a larger market share[30]. - Market expansion efforts are focused on increasing distribution channels in rural areas, aiming for a 30% increase in market penetration by the end of the year[30]. - A new marketing strategy has been implemented, focusing on digital platforms, which is anticipated to increase brand awareness by 25%[30]. - Dain Pharmaceutical's marketing strategy focuses on "expert recommendations, convenient purchasing channels, and professional category education," which has helped increase the penetration rate of its main products[35]. Financial Position - The company reported a significant increase in other income, which rose by 513.86% to ¥24,734,465.89 due to increased government subsidies[43]. - The company reported a loss of CNY 1,195,607.40 from equity method investments during the reporting period[25]. - The company has not classified any non-recurring gains and losses as regular gains and losses, ensuring compliance with disclosure regulations[25]. - The company has not engaged in any significant related party transactions during the reporting period[83]. - The company has not experienced any major litigation or arbitration matters during the reporting period[82]. - The company has not conducted any asset or equity acquisitions or sales during the reporting period[84]. Environmental Compliance - The company holds a valid pollution discharge permit until July 29, 2025, and complies with environmental monitoring requirements[70]. - In the first half of 2023, the company invested approximately CNY 1.349 million in environmental governance and protection efforts[73]. - The company has implemented an automatic online monitoring system for pollution sources, ensuring compliance with wastewater, soil, and noise standards[73]. - The company reported no administrative penalties related to environmental issues during the reporting period[73]. Risks and Challenges - The company faces risks from declining birth rates, impacting sales of children's pharmaceuticals, and plans to enhance market penetration and product offerings[60]. - The company anticipates intensified competition in its core product areas due to new generic drugs entering the market[61]. - DaYin Pharmaceutical is addressing the risk of drug procurement policies by increasing brand influence and expanding marketing channels[61]. Shareholder Information - The total number of shares is 234,331,485, with 99.95% being unrestricted shares[103]. - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[106]. - The total number of common shareholders at the end of the reporting period is 18,203[105]. Financial Reporting - The financial report for the first half of 2023 has not been audited[113]. - The financial statements comply with accounting standards and accurately reflect the company's financial position as of June 30, 2023, and the operating results for the first half of 2023[154]. - The company has confirmed that there are no significant factors affecting its ability to continue as a going concern[152].

证券代码：000915 证券简称：华特达因 公告编号：2023-023 山东华特达因健康股份有限公司 第十届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十届董事会于 2023 年 8 月 7 日以电子邮件形式发出召开第九次会议的通知，并于 2023 年 8 月 17 日在公司会议室召开会议。会议应参加董事8 名，实际参加董事8名。 会议由公司董事长朱效平主持。会议符合有关法律、法规、规章和《公 司章程》的规定。 二、董事会会议审议情况 1.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2023 年半年度报告》； 2.以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关于 2022 年度公司高管薪酬的议案"。 特此公告 山东华特达因健康股份有限公司董事会 2023 年 8 月 19 日 三、备查文件 经与会董事签字并加盖董事会印章的董事会决议。 ...

山东华特达因健康股份有限公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | | 占用方与上市公司 | 上市公司 | 2023 年期 | | 2023 年 1-6 | 月占 | 2023 年 1-6 月 | | 2023 年 | 1-6 | 2023 年 | 6 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | 的关联关系 | 核算的会 | 初占用资 | | 用累计发生金额 | | 占用资金的利 | | 月偿还累计 | | 月末占用 | | 原因 | | | | | | 计科目 | 金余额 | | （不含利息） | | 息（如有） | | 发生金额 | | 资金余额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | | | | | ...

股票代码：000915 股票简称：华特达因 公告编号：2023-024 山东华特达因健康股份有限公司 第十届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东华特达因健康股份有限公司第十届监事会于 2023 年 8 月 7 日以电子邮件形式发出召开第九次会议的通知，并于 2023 年 8 月 17 日在公司会议室召开会议。会议应参加监事5名，实际参加监事5名。 会议由监事会主席郑波先生主持。会议符合有关法律、法规、规章和 《公司章程》的规定。 （三）备查文件 经与会监事签字并加盖监事会印章的监事会决议。 特此公告 二、监事会会议审议情况 以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2023 年半年度报告》并发表如下审核意见： 经审核，监事会认为董事会编制和审议《公司 2023 年半年度报 告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容真 实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 山东华特达因健康股份有限公司监事会 2023 年 ...

独立董事关于公司第十届董事会第九次会议 相关内容的独立意见 关于控股股东及其他关联方占用公司资金、 公司对外担保情况的专项说明和独立意见 根据中国证监会《上市公司监管指引第 8 号——上市公司资金往来、 对外担保的监管要求》（证监会公告〔2022〕26 号）、深圳证券交易所《上 市公司自律监管指引第 1 号——主板上市公司规范运作》的规定和要求， 我们对山东华特达因健康股份有限公司（简称"公司"）的控股股东及其 他关联方占用公司资金的情况、公司对外担保情况进行了核查，现发表专 项说明和独立意见如下： 一、2023年1-6月，公司不存在控股股东及其关联方占用上市公司资 金的情况，也没有前期发生延续至本期的情况。 二、截至 2023 年 6 月末公司实际对外担保额为 1,407.51 万元，上述 金额均是公司为控股股东山东华特控股集团有限公司提供的反担保所致， 担保额占公司净资产的 0.52%。担保履行了《公司章程》规定的审批程序， 不存在损害公司和股东利益的情形。 独立董事：吕玉芹 张志元 杜宁 2023 年 8 月 17 日 关于对公司高管薪酬的独立意见 山东华特达因健康股份有限公司第十届董事会第九次会议审议 ...

Financial Performance - In Q1 2023, the company achieved operating revenue of CNY 561 million, a decrease of 7.28% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 164 million, reflecting a growth of 4.94% year-on-year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported operating revenue of CNY 550 million and net profit of CNY 315 million, with year-on-year increases of 2.98% and 10.13%, respectively[4] - Total operating revenue for Q1 2023 was CNY 561,439,253.57, a decrease of 7.26% compared to CNY 605,516,557.27 in Q1 2022[15] - Net profit for Q1 2023 was CNY 314,399,174.09, representing an increase of 6.00% from CNY 294,239,667.77 in Q1 2022[15] - The company reported a net profit attributable to shareholders of CNY 163,725,554.07 for Q1 2023, compared to CNY 156,021,080.23 in Q1 2022, reflecting an increase of approximately 4.3%[16] - Total comprehensive income for Q1 2023 was CNY 314,399,174.09, compared to CNY 294,239,667.77 in Q1 2022, indicating an increase of approximately 6.8%[16] Cash Flow and Liquidity - The net cash flow from operating activities increased by 21.41% to CNY 335 million compared to the previous year[5] - Net cash flow from operating activities for Q1 2023 was CNY 335,465,224.39, up from CNY 276,299,060.18 in the same period last year, indicating a growth of about 21.4%[16] - The company experienced a net cash outflow from investing activities of CNY -106,073,536.81 in Q1 2023, compared to a net inflow of CNY 46,462,512.22 in Q1 2022[16] - Cash flow from financing activities showed a net outflow of CNY -235,465,952.17 in Q1 2023, contrasting with a net inflow of CNY 3,842,061.89 in Q1 2022[17] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 1,732,064,421.56, a decrease from CNY 1,528,339,147.89 at the end of Q1 2022[17] Assets and Liabilities - Total assets at the end of Q1 2023 reached CNY 4.82 billion, up 2.73% from the end of the previous year[5] - The company's total assets increased to CNY 4,818,661,151.84, up from CNY 4,690,492,822.90 at the end of Q1 2022[14] - Total liabilities rose to CNY 947,209,068.42, compared to CNY 629,027,439.57 in the same period last year[14] - The equity attributable to shareholders increased by 6.34% to CNY 2.75 billion compared to the end of the previous year[5] - The equity attributable to shareholders of the parent company increased to CNY 2,747,813,822.68, up from CNY 2,584,088,268.61 year-over-year[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,304[11] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[11] - The company reported a total of 10 major shareholders with varying percentages of ownership, the largest being 22.00%[11] Other Financial Metrics - The company reported a significant increase in accounts receivable by 65.17% to CNY 89.52 million, primarily due to the increase in receivables from the subsidiary[8] - Other receivables surged by 100.93% to CNY 19.04 million, attributed to increased government subsidy receivables[8] - The company experienced a 603.93% increase in other income, totaling CNY 14.91 million, mainly due to higher government subsidies[8] - The company’s basic earnings per share rose by 4.48% to CNY 0.70 per share[5] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.70, up from CNY 0.67 in Q1 2022, marking a growth of about 4.5%[16] Research and Development - Research and development expenses for Q1 2023 were CNY 11,073,221.93, a decrease from CNY 12,769,669.95 in Q1 2022[15] Future Outlook - Future outlook includes continued focus on market expansion and new product development to drive growth[15]

证券代码：000915 证券简称：华特达因 | 挂，已经比大股东增持 1%的时候低，请问大股东有增持计划 | | --- | | 吗？ | | 答：您好，公司目前没有接到大股东的增持计划。 | | 5.问：公司今年会被纳入医药集采么？除了伊可新外，其 | | 他产品年度业绩目标如何？ | | 答：您好，除伊可新等主要产品外，右旋糖酐铁颗粒及复 | | 方碳酸钙泡腾颗粒也是公司 2023 年重点推广产品。 | | 6.问：请问专注医药主营的具体措施，有没有同行业并购 | | 计划，剥离非医药的进程。 | | 答：您好。公司专注儿童制药及健康领域，对非主业将在 | | 发展的基础上择机退出。如有符合企业发展战略的并购标的， | | 公司不排除通过并购方式实现快速发展。 | | 7.问：公司第一季度销售状况？ | | 答：您好，关于公司 2023 年第一季度经营情况，请您关 | | 注公司 2023 年第一季度报告。 | | 8. 问：关心下一代健康成长是中华人民长治久安的根本 | | 前提，也是中华人民尊老爱幼优良传统，请问：（1）公司未 | | 来如何布局儿童健康成长产业，有哪些前瞻设想，并已经开始 | | 了 ...

证券代码：000915 证券简称：华特达因 公告编号：2023-011 山东华特达因健康股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）定于 2023 年 3 月 30 日（周四）16:00-17:00 在全景网举办 2022 年年度报告业 绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次 年度业绩说明会。 公司出席本次说明会的人员有：总经理杨杰女士、独立董事吕玉 芹女士、董事会秘书范智胜先生、财务负责人王伟女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投资者可于 2023 年 3 月 29 日（ 星 期 三 ） 15 ： 00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页 面。公司将在 2022 年度业绩说明会上，对投资者 ...